Insight Molecular Diagnostics insider buys $6M in shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
At Insight Molecular Diagnostics Inc. (IMDX), 10% owner Broadwood Partners, L.P. purchased 3,428,571 common shares from the company in an underwritten public offering on November 17, 2026, for $1.75 per share and a total purchase price of $5,999,999.25. No Rule 10b5-1 plan is reported. A related indirect ownership entry lists 16,113,455 shares following the transaction. The report also lists currently exercisable warrants for 150,093 common shares at $30.60, expiring April 19, 2027. Broadwood Capital, Inc., Broadwood Partners' general partner, and Neal C. Bradsher, a 10% owner and president of Broadwood Capital, may be deemed beneficial owners. Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, no par value F3, F1 | 3,428,571 | $1.75 | $6.00M |
| Purchase | Common Stock, no par value F1 | 0 | $0.00 | $0.00 |
| Holding | Warrant to Purchase Common Stock F4, F1 | -- | -- | -- |
| Holding | Warrant to Purchase Common Stock F4, F1 | -- | -- | -- |
| Holding | Common Stock, no par value F2 | -- | -- | -- |
Footnotes (4)
- F1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F2. These securities are directly owned by Neal C. Bradsher.
- F3. On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share.
- F4. These warrants are currently exercisable.
Key Figures
Key Terms
underwritten public offering financial
beneficially owned regulatory
pecuniary interest regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What warrant position did the IMDX ownership report list?
AI-generated analysis. How Rhea-AI works. Not financial advice.